On July 27, the U.S. House of Representatives passed the Gabriella Miller Kids First Research Act 2.0 (H.R. 623). This legislation extends funding for this pediatric disease research program within the National Institutes of Health (NIH). Funding is provided by certain penalties assessed by the Securities and Exchange Commission against pharmaceutical companies. In making allocations from the fund, the NIH must prioritize pediatric research that does not duplicate existing research activities.
Washington E-Newsletter
